RxDoctor Payments Data

Tamaura Baughman, APRN

Family · Kingwood, TXNPI 1437520921

Payments from drug & device makers

$2,690in general payments, 2019–2025

Across 160 payments — averaging $16.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$485
  • Otsuka America Pharmaceutical, Inc.$404
  • Lilly USA, LLC$263
  • GSK$199
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$185
  • Takeda Pharmaceuticals U.S.A., Inc.$159
  • plus $996 from 23 others

What the payments were for

  • Food & beverage$2,690100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,690 in reported general payments places this provider in the 85th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$2,643,953
Medicare patients
16
Services billed
1,303

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban129$95,819
OzempicSemaglutide73$94,359
XareltoRivaroxaban50$48,640
JanuviaSitagliptin Phosphate45$39,374
MounjaroTirzepatide31$37,190
RybelsusSemaglutide22$33,703
MyrbetriqMirabegron44$28,570
EntrestoSacubitril/Valsartan38$26,571
RexultiBrexpiprazole16$25,208
Tresiba Flextouch U-200Insulin Degludec29$21,274
LinzessLinaclotide23$19,803
FarxigaDapagliflozin Propanediol22$18,738
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$14,459
Breo ElliptaFluticasone/Vilanterol23$11,884
GemtesaVibegron16$9,783

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$485$128,06195 claims
PfizerEliquis$20$95,819129 claims
MerckJanuvia, Belsomra$57$46,33060 claims
Lilly USA, LLCMounjaro$263$37,19031 claims
Astellas Pharma US IncMyrbetriq$54$28,57044 claims
GSKTrelegy Ellipta, Breo Ellipta$199$26,34341 claims
Otsuka America Pharmaceutical, Inc.Rexulti$404$25,20816 claims
AstraZenecaFarxiga, Brilinta$46$24,26334 claims
AbbVieLinzess$119$19,80323 claims
Sumitomo Pharma America, Inc.Gemtesa$65$9,78316 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 15,456 family providers in Texas.

Other family in Kingwood

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →